Colon cancer clues: DNA repair status may guide surgery decisions
NCT ID NCT06798857
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at 1,471 colon cancer patients to see how their tumor's DNA repair status (pMMR vs dMMR) relates to lymph node spread and survival. Researchers hope to identify patients who might not need extensive lymph node removal. The study is observational and does not test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors decide which colon cancer patients can safely avoid extensive lymph node removal during surgery.
- What could go wrong
- This is an observational analysis of past data, not a treatment trial. The findings may not change practice without further prospective studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
1,471 people
The number who actually took part.
- Started
-
Apr 2009
- Finished
-
Sep 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study subjects were colon cancer patients who received radical surgical treatment at the Sixth Affiliated Hospital of Sun Yat-Sen University from January 2010 to December 2021. Patients must not have received neoadjuvant chemoradiotherapy and have a clear MMR status and necessary clinical and pathological information as well as follow-up prognostic information
- Ages
-
20 to 90 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * The preoperative diagnosis was primary colon adenocarcinoma; * Undergoing radical surgical treatment; * Postoperative immunohistochemistry to determine MMR status; * Having complete key clinical and follow-up data. Exclusion Criteria: * Previous history of malignant tumors * Concurrent distant metastasis * Receiving preoperative neoadjuvant therapy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colon adenocarcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a personalized menu keep cancer patients stronger through chemotherapy?
- Can surgeons spare nerves and still cure colon cancer?
- New injectable drug tested against Hard-to-Treat solid tumors
- The gatekeepers of tumors: scientists probe how blood vessels let immune cells in
- Blood test could guide stronger chemo for colon cancer
- Blood test aims to catch Cancer's return earlier